Showing 1‐2 of 2
White paper
16 min read
How Optimizing Process Parameters Can Improve Scalability and Manufacturability of a Cytotoxic Antibody Drug Conjugate
Antibody-drug conjugates (ADCs) are a growing drug class consisting of a monoclonal antibody (mAb) attached to a cytotoxic drug via a linker. In 2021, eleven US Food and Drug Administration (FDA) approved ADCs were available [1] to treat a range of blood ...
Presentation (on-demand)
Diversification of ADC formats and overcoming purification challenges
Bioconjugation is a chemical strategy to form a stable covalent link between two molecules, at least one of which is a biomolecule such as a protein. A very prominent type of bioconjugate is antibody-drug conjugates (ADCs), which is a powerful class of th...